Real-world impact of fremanezumab on migraine-related health care utilization and costs in patients with common comorbidities, acute medication overuse, or difficult-to-treat migraine

被引：0
|
作者：
Buse, D. C. [1 ,2 ]
Driessen, M. T. [3 ]
Krasenbaum, L. J. [4 ]
Seminerio, M. J. [5 ,6 ]
Carr, K. [5 ]
Ortega, M. [5 ]
Packnett, E. R. [7 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[5] Teva Pharmaceut, Parsippany, NJ USA
[6] Teva Pharmaceut, W Chester, PA USA
[7] IBM Watson Hlth, Cambridge, MA USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-91
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [1] A US CLAIMS DATABASE ANALYSIS OF THE IMPACT OF FREMANEZUMAB ON MIGRAINE-RELATED HEALTH CARE UTILIZATION AND COSTS IN PATIENTS WITH COMMON COMORBIDITIES, ACUTE MEDICATION OVERUSE, OR DIFFICULT-TO-TREAT MIGRAINE
    Buse, D. C.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Carr, K.
    Ortega, M.
    Packnett, E.
    VALUE IN HEALTH, 2022, 25 (07) : S419 - S420
  • [2] Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
    Buse, Dawn C.
    Krasenbaum, Lynda J.
    Seminerio, Michael J.
    Packnett, Elizabeth R.
    Carr, Karen
    Ortega, Mario
    Driessen, Maurice T.
    PAIN AND THERAPY, 2024, 13 (03) : 511 - 532
  • [3] US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab
    Seminerio, Michael
    Tangirala, Krishna
    Thompson, Stephen F.
    Ariely, Rinat
    Cohen, Joshua M.
    Carr, Karen
    Buse, Dawn C.
    NEUROLOGY, 2021, 96 (15)
  • [4] A RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE IMPACT OF FREMANEZUMAB ON MIGRAINE-RELATED HEALTH CARE UTILIZATION AND COSTS IN PATIENTS WITH POTENTIAL ACUTE MEDICATION OVERUSE
    Buse, D. C.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Carr, K.
    Ortega, M.
    Packnett, E.
    VALUE IN HEALTH, 2022, 25 (07) : S338 - S338
  • [5] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    HEADACHE, 2021, 61 : 71 - 72
  • [6] Impact of Fremanezumab on Migraine-related Health Care Resource Utilization and Costs in US Patients With Migraine and Comorbid Depression and/or Anxiety
    Buse, Dawn C.
    Driessen, Maurice T.
    Krasenbaum, Lynda J.
    Akcicek, Hasan
    Lyras, Leonidas
    Packnett, Elizabeth R.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 78 - 79
  • [7] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
  • [8] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [9] Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants
    Eugeni, P.
    Rooney, M. E.
    Saikali, N. P.
    Niu, Z.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    McVige, J. W.
    HEADACHE, 2022, 62 : 158 - 158
  • [10] Real-world Reductions in Migraine-related Healthcare Resource Utilization for German Patients Initiating Fremanezumab
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yilma, B.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 420 - 420
12345